EVEREST MED (01952) announced that on December 11, 2025, Everest Medicines (a wholly-owned subsidiary of the company) entered into a commercialization service agreement with Hissen Bio. Under this agreement, the subsidiary will provide CSO services for products in China.
The board believes that this agreement will enable the group to leverage its existing geographic footprint, channel access, and hospital coverage to create synergies in regions and customer segments where Hissen Bio has yet to achieve full penetration. By serving as a CSO provider for mature products, the group aims to strengthen product lifecycle management and commercialization capabilities while generating recurring service fee revenue, thereby improving the utilization and productivity of its existing commercial platform.
With established infrastructure, sales teams, and key customer relationships, the company is confident in driving incremental sales while scaling up its commercial organization’s experience and efficiency.
Additionally, effective December 11, 2025, Everest Medicines and Hissen Bio entered into a licensing agreement. Under this pact, Hissen Bio granted the subsidiary a non-transferable and non-assignable exclusive license (even binding on Hissen Bio and its affiliates), along with limited rights to sublicense under the licensor’s patents and proprietary know-how. These rights are strictly for the development, commercialization, use, sale, offering for sale, export, and import of licensed compounds and products within the designated region and field.
Separately, Mr. Sun Xin has been appointed as a non-executive director, effective December 11, 2025.
Comments